Enerji Homeostazını Düzenleyen Peptitlerin Diyabetteki Rolleri
Özet
Dünya genelinde prevalansı hızla artan diyabet, enerji dengesinin bozulmasıyla karakterize kronik bir metabolik hastalıktır. Bu denge; gastrointestinal sistem, yağ dokusu ve merkezi sinir sisteminden salgılanan peptitler aracılığıyla iştah ve enerji harcanmasının koordinasyonuyla sağlanır. Hipotalamusun temel koordinatör olduğu bu süreçte, ghrelin gibi oreksijenik (iştah artırıcı) ve leptin, GLP-1, amilin gibi anoreksijenik (iştah azaltıcı) peptitler kritik roller üstlenir. Diyabet yönetiminde özellikle GLP-1 analogları ve amilin türevi pramlintid gibi peptit bazlı tedaviler, insülin sekresyonunu artırıp glukoz seviyelerini düzenleyerek klinik başarı göstermektedir. Ayrıca son dönem araştırmaları adropin ve speksin gibi yeni peptitlerin düşük seviyelerinin insülin direnci ve obezite ile doğrudan ilişkili olduğunu, bu moleküllerin potansiyel biyobelirteç veya terapötik hedef olabileceğini ortaya koymaktadır. Glukagon ve GLP-1 ikili agonistleri gibi hibrit yaklaşımlar ise hem kilo kaybı hem de glisemik kontrol sağlamada umut verici sonuçlar sunmaktadır. Sonuç olarak, beyin-bağırsak eksenindeki peptit etkileşimlerinin derinlemesine anlaşılması, diyabetin daha etkin yönetimi için yeni tedavi yöntemlerinin geliştirilmesine olanak tanımaktadır.
Diabetes, whose prevalence is rapidly increasing worldwide, is a chronic metabolic disease characterized by impaired energy balance. This balance is maintained through the coordination of appetite and energy expenditure by peptides secreted from the gastrointestinal system, adipose tissue, and the central nervous system. In this process where the hypothalamus is the primary coordinator, orexigenic (appetite-stimulating) peptides like ghrelin and anorexigenic (appetite-suppressing) peptides like leptin, GLP-1, and amylin play critical roles. In diabetes management, peptide-based treatments such as GLP-1 analogs and the amylin derivative pramlintide show clinical success by increasing insulin secretion and regulating glucose levels. Additionally, recent research reveals that low levels of novel peptides like adropin and spexin are directly associated with insulin resistance and obesity, suggesting these molecules could be potential biomarkers or therapeutic targets. Hybrid approaches, such as glucagon and GLP-1 dual agonists, offer promising results in providing both weight loss and glycemic control. Consequently, a deep understanding of peptide interactions in the brain-gut axis enables the development of new treatment methods for more effective diabetes management.
Referanslar
Gurusamy, N. The potential of mesenchymal stem cells in diabetes mellitus. Diabesity 2017;3(1): 1-4. doi:10.15562/diabesity.2017.37
Waterson MJ, Horvath TL. Neuronal regulation of energy homeostasis: Beyond the hypothalamus and feeding. Cell Metab. 2015;22(6): 962-70. doi: 10.1016/j.cmet.2015.09.026. Epub 2015 Oct 22. PMID: 26603190.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28 Suppl 1: S37-42. doi: 10.2337/diacare.28.suppl_1.s37. PMID: 15618111.
Berbesque JC, Marlowe FW, Shaw P, et al. Hunter-gatherers have less famine than agriculturalists. Biol Lett. 2014;10(1): 20130853. doi: 10.1098/rsbl.2013.0853. PMID: 24402714; PMCID: PMC3917328.
Arusoğlu G, Köksal G. Besin alımı ve enerji dengesi. Bes Diy Derg [Internet]. 2015;43(1): 51-8. (03.02.2022 tarihinde https://www.beslenmevediyetdergisi.org/index.php/bdd/article/view/125 adresinden ulaşılmıştır.)
Şahin A, Yalnız M. Obezite ve gastrointestinal sistem ilişkisi. Fırat Tıp Dergisi, 2018;23: 22-29.
Bhat VK, Kerr BD, Flatt PR, et al. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochem Pharmacol. 2013;85(11): 1655-62. doi: 10.1016/j.bcp.2013.03.009. Epub 2013 Mar 18. PMID: 23518155.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1: S81-90. doi: 10.2337/dc14-S081. PMID: 24357215.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010. 33 Suppl 1(Suppl 1): S62-9. doi: 10.2337/dc10-S062. Erratum in: Diabetes Care. 2010;33(4):e57. PMID: 20042775; PMCID: PMC2797383.
Thunander M, Törn C, Petersson C, et al. Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden. Eur J Endocrinol. 2012;166(6): 1021-9. doi: 10.1530/EJE-11-0797. Epub 2012 Mar 21. PMID: 22436402; PMCID: PMC3361790.
Inzucchı SE, Sherwın RS. Type 2 diabetes mellitus. Cecil Medicine. 24th ed. Philadelphia, Pa: Saunders Elsevier, 2011.
Döğer E. Enerji homeostazı. In: Cinaz P (ed), Obezite. 1. Baskı. Ankara: Türkiye Klinikleri; 2020. p.1-9.
Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352(11): 1138-45. doi: 10.1056/NEJMsr043743. PMID: 15784668.
Hızlı GH. Yüksek yağlı diyetin açlık-tokluk metabolizmasında görevli hormonlar ve nöropeptidler üzerine etkileri. JHS. 2018; 27(3): 239-344.
Milbank E, López M. Orexins/hypocretins: Key regulators of energy homeostasis. Front Endocrinol (Lausanne). 2019 Dec 10;10:830. doi: 10.3389/fendo.2019.00830. PMID: 31920958; PMCID: PMC6918865.
Koliaki C, Liatis S, Dalamaga M, et al. The ımplication of gut hormones in the regulation of energy homeostasis and their role in the pathophysiology of obesity. Curr Obes Rep. 2020;9(3): 255-271. doi: 10.1007/s13679-020-00396-9. PMID: 32647952.
Irwin N, Frizelle P, Montgomery IA, et al. Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes. Diabetologia. 2012;55(10): 2747-2758. doi: 10.1007/s00125-012-2654-6. Epub 2012 Jul 20. PMID: 22814764.
Pathak V, Flatt PR, Irwin N. Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes. Peptides. 2018;100: 229-235. doi: 10.1016/j.peptides.2017.09.007. PMID: 29412823.
Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21): 1623-30. doi: 10.1056/NEJMoa012908. PMID: 12023994.
Büyükuslu DDN. İştah-doygunluk metabolizmasını etkileyen faktörler. Pediatri. 2019;11(1): 22-28. (03.02.2022 tarihinde https://dergipark.org.tr/tr/pub/ktpd/issue/47815/602769 adresinden ulaşılmıştır.)
Korek E, Krauss H, Gibas-Dorna M, et al. Fasting and postprandial levels of ghrelin, leptin and insulin in lean, obese and anorexic subjects. Prz Gastroenterol. 2013;8(6): 383-9. doi: 10.5114/pg.2013.39922. Epub 2013 Dec 30. PMID: 24868288; PMCID: PMC4027830.
Alamri BN, Shin K, Chappe V, et al. The role of ghrelin in the regulation of glucose homeostasis. Horm Mol Biol Clin Investig. 2016;26(1): 3-11. doi: 10.1515/hmbci-2016-0018. PMID: 27235674.
Pöykkö SM, Kellokoski E, Hörkkö S, et al. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003;52(10): 2546-53. doi: 10.2337/diabetes.52.10.2546. PMID: 14514639.
Kacar AK, Sacan O, Ozıclı N, et al. The effects of ghrelin on renal complications in newborn diabetic rats. Eur J Biol. 2020;79(1): 1-6. doi: 10.26650/EurJBiol.2020.0043
Artaş G, Kuloğlu T. Enalaprilin diyabetik sıçan mide dokusunda ghrelin ekspresyonuna etkileri. Fırat Tıp Dergisi. 2014;19(4): 172-176.
Margetic S, Gazzola C, Pegg GG, et al. Leptin: A review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26(11): 1407-33. doi: 10.1038/sj.ijo.0802142. PMID: 12439643.
Park HK, Ahima RS. Physiology of leptin: Energy homeostasis, neuroendocrine function and metabolism. Metabolism. 2015;64(1): 24-34. doi: 10.1016/j.metabol.2014.08.004. Epub 2014 Aug 15. PMID: 25199978; PMCID: PMC4267898.
Dalamaga M, Chou SH, Shields K, et al. Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab. 2013;18(1): 29-42. doi: 10.1016/j.cmet.2013.05.010. Epub 2013 Jun 13. PMID: 23770129.
Ahima RS, Osei SY. Leptin signaling. Physiol Behav. 2004;81(2): 223-41. doi: 10.1016/j.physbeh.2004.02.014. PMID: 15159169.
Sader S, Nian M, Liu P. Leptin: A novel link between obesity, diabetes, cardiovascular risk, and ventricular hypertrophy. Circulation. 2003;108(6): 644-6. doi: 10.1161/01.CIR.0000081427.01306.7D. PMID: 12912793.
Moran SA, Patten N, Young JR, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism. 2004;53(4): 513-9. doi: 10.1016/j.metabol.2003.10.019. PMID: 15045701.
Adamska E, Ostrowska L, Górska M, et al. The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes. Prz Gastroenterol. 2014;9(2): 69-76. doi: 10.5114/pg.2014.42498. Epub 2014 May 5. PMID: 25061485; PMCID: PMC4108747.
Maffeis C, Surano MG, Cordioli S, et al. A high-fat vs. a moderate-fat meal in obese boys: Nutrient balance, appetite, and gastrointestinal hormone changes. Obesity (Silver Spring). 2010;18(3): 449-55. doi: 10.1038/oby.2009.271. Epub 2009 Aug 27. PMID: 19713952.
Khoo B, Tan TM. Combination gut hormones: Prospects and questions for the future of obesity and diabetes therapy. J Endocrinol. 2020;246(3): R65-R74. doi: 10.1530/JOE-20-0119. PMID: 32438346.
Steinert RE, Feinle-Bisset C, Asarian L, et al. Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev. 2017;97(1): 411-463. doi: 10.1152/physrev.00031.2014. Erratum in: Physiol Rev. 2017 Jul 1;97(3):1229. PMID: 28003328; PMCID: PMC6151490.
Ma RC, Xu G. Incretin action on bone: An added benefit? J Diabetes Investig. 2015;6(3): 267-8. doi: 10.1111/jdi.12273. Epub 2014 Sep 15. PMID: 25969710; PMCID: PMC4420557.
Nie Y, Ma RC, Chan JC, et al. Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes. FASEB J. 2012;26(6): 2383-93. doi: 10.1096/fj.11-196782. Epub 2012 Feb 24. PMID: 22366643.
Christensen M, Bagger JI, Vilsbøll T, et al. The alpha-cell as target for type 2 diabetes therapy. Rev Diabet Stud. 2011;8(3): 369-81. doi: 10.1900/RDS.2011.8.369. Epub 2011 Nov 10. PMID: 22262074; PMCID: PMC3280671.
Thondam SK, Daousi C, Wilding JP, et al. Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. Am J Physiol Endocrinol Metab. 2017;312(3): E224-E233. doi: 10.1152/ajpendo.00347.2016. Epub 2017 Jan 10. PMID: 28073779.
Reda TK, Geliebter A, Pi-Sunyer FX. Amylin, food intake, and obesity. Obes Res. 2002;10(10): 1087-91. doi: 10.1038/oby.2002.147. PMID: 12376591.
Buhmann H, le Roux CW, Bueter M. The gut-brain axis in obesity. Best Pract Res Clin Gastroenterol. 2014;28(4): 559-71. doi: 10.1016/j.bpg.2014.07.003. Epub 2014 Jul 11. PMID: 25194175.
Press M, Jung T, König J, et al. Protein aggregates and proteostasis in aging: Amylin and β-cell function. Mech Ageing Dev. 2019;177: 46-54. doi: 10.1016/j.mad.2018.03.010. Epub 2018 Mar 23. PMID: 29580826.
Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006;29(10): 2189-95. doi: 10.2337/dc06-0042. PMID: 17003291.
Smith SR, Blundell JE, Burns C, et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab. 2007;293(2): E620-7. doi: 10.1152/ajpendo.00217.2007. Epub 2007 May 15. PMID: 17505051.
Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004;12(4): 661-8. doi: 10.1038/oby.2004.76. PMID: 15090634.
Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010;122(11 Suppl): S185-92. doi: 10.1161/CIRCULATIONAHA.109.931782. PMID: 20837912.
Choi HN, Yim JE. Plasma adropin as a potential marker predicting obesity and obesity-associated cancer in korean patients with type 2 diabetes mellitus. J Cancer Prev. 2018;23(4): 191-196. doi: 10.15430/JCP.2018.23.4.191. Epub 2018 Dec 30. PMID: 30671402; PMCID: PMC6330988.
Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6): 468-81. doi: 10.1016/j.cmet.2008.10.011. PMID: 19041763; PMCID: PMC2746325.
Akcilar R, Kocak FE, Simsek H, et al. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy. 2016;117(2): 100-5. doi: 10.4149/bll_2016_020. PMID: 26830041.
Wu L, Fang J, Chen L, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014;52(5): 751-8. doi: 10.1515/cclm-2013-0844. PMID: 24323892.
Porzionato A, Rucinski M, Macchi V, et al. Spexin expression in normal rat tissues. J Histochem Cytochem. 2010;58(9): 825-37. doi: 10.1369/jhc.2010.956300. Epub 2010 Jun 7. PMID: 20530460; PMCID: PMC2924798.
Gu L, Ma Y, Gu M, et al. Spexin peptide is expressed in human endocrine and epithelial tissues and reduced after glucose load in type 2 diabetes. Peptides. 2015;71: 232-9. doi: 10.1016/j.peptides.2015.07.018. Epub 2015 Jul 23. PMID: 26211893.
Karaca A, Bakar-Ates F, Ersoz-Gulcelik N. Decreased spexin levels in patients with type 1 and type 2 diabetes. Med Princ Pract. 2018;27(6): 549-554. doi: 10.1159/000493482. Epub 2018 Sep 5. PMID: 30184546; PMCID: PMC6422114.
Kumar S, Hossain J, Nader N, et al. Decreased circulating levels of spexin in obese children. J Clin Endocrinol Metab. 2016;101(7): 2931-6. doi: 10.1210/jc.2016-1177. Epub 2016 May 24. PMID: 27218269; PMCID: PMC4929838.
Halban PA, Polonsky KS, Bowden DW, et al. β-cell failure in type 2 diabetes: Postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab. 2014;99(6): 1983-92. doi: 10.1210/jc.2014-1425. Epub 2014 Apr 8. PMID: 24712577; PMCID: PMC5393482.
Lancha A, Frühbeck G, Gómez-Ambrosi J. Peripheral signalling involved in energy homeostasis control. Nutr Res Rev. 2012;25(2): 223-48. doi: 10.1017/S0954422412000145. PMID: 23174510.
Bewick GA. Bowels control brain: Gut hormones and obesity. Biochem Med (Zagreb). 2012;22(3): 283-97. doi: 10.11613/bm.2012.032. PMID: 23092061; PMCID: PMC3900054.
Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10): 2258-66. doi: 10.2337/db09-0278. Epub 2009 Jul 14. PMID: 19602537; PMCID: PMC2750209.
Cegla J, Troke RC, Jones B, et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes. 2014;63(11): 3711-20. doi: 10.2337/db14-0242. Epub 2014 Jun 17. PMID: 24939425.
Holst JJ, Albrechtsen NJW, Gabe MBN, et al. Oxyntomodulin: Actions and role in diabetes. Peptides. 2018;100: 48-53.doi: 10.1016/j.peptides.2017.09.018. PMID: 29412831.
Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond). 2006;30(12): 1729-36. doi: 10.1038/sj.ijo.0803344. Epub 2006 Apr 18. PMID: 16619056.
Ambery P, Parker VE, Stumvoll M, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391(10140): 2607-2618. doi: 10.1016/S0140-6736(18)30726-8. Epub 2018 Jun 23. PMID: 29945727.
